Dr L’Erario discusses neurologic care for TGD patients, highlighting key challenges, best practices, & steps toward more ...

For stroke survivors, talking therapy is associated with moderate reductions in depression and large reductions in anxiety ...

Genetic variants of narcolepsy are tied to sleep characteristics including sleep efficiency, wake up time, and difficulty sleeping through the night.

Erenumab significantly improved quality of life and disability among patients with chronic and episodic migraine over a 2-year period.

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

Decreases in global cognition and executive function, as well as long-term persistent declines in those cognitive domains, are associated with incident HF.

Approximately one-third of pediatric mental health emergency department visits resulting in admission or transfer exceeded 12 hours.

Certain objectively measured daytime napping behaviors are associated with an increased risk for mortality for middle- to older-aged adults.

The FDA has accepted for review the resubmitted NDA for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease.

Both CPAP and tirzepatide are acceptable treatments for comorbid obesity and OSA, with providers favoring CPAP and patients preferring tirzepatide.

The FDA has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.